# Single Dose Investigator Initiated Pilot Study to Investigate CYTALUX (Pafolacianine) for Intraoperative Detection of Malignant Tissue in Subjects Undergoing Surgical Resection for Cancer

Source: https://onco.cc/trials/nct07039526/  
OnCo record `nct07039526` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Pafolacianine in Oesophageal cancer, run by John Waters, now recruiting.

## Summary

Single Dose Investigator Initiated Pilot Study to Investigate CYTALUX (Pafolacianine) for Intraoperative Detection of Malignant Tissue in Subjects Undergoing Surgical Resection for Cancer is a phase 2 interventional study registered as NCT07039526 by John Waters, with 50 participants planned, started 2025-08-19 and due to reach its primary completion in 2027-12. Interventions recorded: CYTALUX™ (pafolacianine) injection preoperatively. Conditions recorded: Esophageal Cancer, Gastrointestinal Cancers, Gynecologic Cancers.

Linked to the drug Pafolacianine because the registry names it among its interventions and Oesophageal cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07039526
- Phase: 2
- Setting: Single Dose Investigator Initiated Pilot Study to Investigate CYTALUX (Pafolacianine) for Intraoperative Detection of Malignant Tissue in Subjects Undergoing Surgical Resection for Cancer.
- Sponsor: John Waters
- Enrolled: 50

## Sources

- ClinicalTrials.gov NCT07039526: https://clinicaltrials.gov/study/NCT07039526

## Connected records

- cancers: [Oesophageal cancer](https://onco.cc/cancers/esophageal/)
- drugs: [Pafolacianine](https://onco.cc/drugs/pafolacianine/)

---
JSON: https://onco.cc/api/v1/entities/nct07039526.json